Targeting PrfA From Listeria Monocytogenes: A Computational Drug Repurposing Approach

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This study reported that dutasteride, identified through a drug repurposing strategy, showed the potential to reduce neuroinflammation and cognitive impairment in LPS-stimulated models.

This study identified ten novel compounds that may effectively target steroid 5 alpha-reductase 2 (5αR-2) for potential treatment of benign prostate hyperplasia, exhibiting comparable binding energies to existing drugs like finasteride and dutasteride.

Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.